Author

Morita Satoshi

Observed names: Prof Satoshi Morita, Satoshi, Morita

Observed institution: Kyoto University

OpenAlex ID: A5140768137

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

2020 · Tatsuro Fukuhara, Haruhiro Saito, et al. · EBioMedicine · 30

Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer

2024 · Sunakawa Yu, Kuboki Yasutoshi, et al. · Institutional Repositories DataBase (IRDB)

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial

2023 · Maruyama Shoichi, Kurasawa Shimon, et al. · Institutional Repositories DataBase (IRDB)

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

2023 · Kuboki Yasutoshi, Terazawa Tetsuji, et al. · Institutional Repositories DataBase (IRDB)

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study

2018 · Nobuaki, Sato, Norikazu, Masuda, et al. · Institutional Repositories DataBase (IRDB)

Works count: 5

Citation count: 30

H-index: 1

I10-index: 1